Molecular overlap between primary immune thrombocytopenia and inherited platelet disorders: A pediatric case report with a novel heterozygous ITGB3 variant identified by next-generation sequencing
- 1School of Medicine, Universidad de los Andes, Bogotá, D.C., Colombia
- 2Department of Pediatric Hematology and Oncology, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia
Abstract
Primary immune thrombocytopenia (ITP) in children is typically self-limited. However, persistent and treatment-resistant cases require evaluation of alternative pathogenic mechanisms. We report a 12-year-old female with persistent ITP unresponsive to corticosteroids and intravenous immunoglobulin, in whom genetic testing identified a rare heterozygous ITGB3 variant (c.1043G>A; p. Ser348Asn) which encodes the β3 subunit of the platelet αIIbβ3 integrin, a receptor essential for platelet aggregation, outside-in signaling, and megakaryocyte maturation. The variant was not found in population databases and was classified as a variant of uncertain significance according to the American College of Medical Genetics and Genomics (ACMG). Integrated silico analyses using AlphaMissense and PolyPhen-2 yielded a suggestive pathogenicity profile. Parental genetic testing confirmed maternal transmission of the variant, with the mother remaining clinically asymptomatic, consistent with autosomal dominant inheritance with incomplete penetrance. Eltrombopag had been initiated before the genetic results became available, in line with standard management of chronic ITP, and produced a sustained platelet response maintained over 26 months of follow-up. This case highlights the value of molecular evaluation in atypical pediatric ITP, while underscoring that the therapeutic response cannot be interpreted as evidence of variant pathogenicity. The reporting of this case conforms to the CARE guidelines.
Related
- Longitudinal TP53 dynamics in repeated tissue-based next-generation sequencing in non-small cell lung cancer: a real-world study with molecular lineage adjudication and sequential credibility verification.
- Advanced Molecular Analysis in Hemophilia A in a Single Step: Next Generation Sequencing (NGS) and Copy Number Variation (CNV) Analysis
- Quantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens
- Diagnostic performance of next-generation sequencing in thyroid nodules and molecular correlates of tumor aggressiveness in papillary thyroid carcinoma
- Juvenile Huntington Disease With Cerebellar‐Predominant Atrophy Identified by Genome Sequencing
BibTeX
@article{rodriguez2026molecular,
title = {{Molecular overlap between primary immune thrombocytopenia and inherited platelet disorders: A pediatric case report with a novel heterozygous ITGB3 variant identified by next-generation sequencing}},
author = {Félix David Duarte Rodríguez and Óscar Eduardo González Figueredo and Alejandra Calderón Gasca},
journal = {Therapeutic Advances in Hematology},
year = {2026},
month = sep,
doi = {10.1177/20406207261491632},
url = {https://doi.org/10.1177/20406207261491632},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Molecular overlap between primary immune thrombocytopenia and inherited platelet disorders: A pediatric case report with a novel heterozygous ITGB3 variant identified by next-generation sequencing
AU - Félix David Duarte Rodríguez
AU - Óscar Eduardo González Figueredo
AU - Alejandra Calderón Gasca
PY - 2026
DA - 2026/09/19
JO - Therapeutic Advances in Hematology
DO - 10.1177/20406207261491632
UR - https://doi.org/10.1177/20406207261491632
AB - Primary immune thrombocytopenia (ITP) in children is typically self-limited. However, persistent and treatment-resistant cases require evaluation of alternative pathogenic mechanisms. We report a 12-year-old female with persistent ITP unresponsive to corticosteroids and intravenous immunoglobulin, in whom genetic testing identified a rare heterozygous ITGB3 variant (c.1043G>A; p. Ser348Asn) which encodes the β3 subunit of the platelet αIIbβ3 integrin, a receptor essential for platelet aggregation, outside-in signaling, and megakaryocyte maturation. The variant was not found in population databases and was classified as a variant of uncertain significance according to the American College of Medical Genetics and Genomics (ACMG). Integrated silico analyses using AlphaMissense and PolyPhen-2 yielded a suggestive pathogenicity profile. Parental genetic testing confirmed maternal transmission of the variant, with the mother remaining clinically asymptomatic, consistent with autosomal dominant inheritance with incomplete penetrance. Eltrombopag had been initiated before the genetic results became available, in line with standard management of chronic ITP, and produced a sustained platelet response maintained over 26 months of follow-up. This case highlights the value of molecular evaluation in atypical pediatric ITP, while underscoring that the therapeutic response cannot be interpreted as evidence of variant pathogenicity. The reporting of this case conforms to the CARE guidelines.
SN - 2040-6207
SN - 2040-6215
ER -